Daratumumab and Donor Lymphocyte Infusion in Treating Participants With Relapsed Acute Myeloid Leukemia After Stem Cell Transplant

NCT03537599 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

TERMINATED

Status

4

Enrollment

OTHER

Sponsor class

Stopped Poor acccrual

Conditions

Minimal Residual Disease
Recurrent Acute Myeloid Leukemia With Myelodysplasia-Related Changes
Recurrent Adult Acute Myeloid Leukemia
Recurrent Childhood Acute Myeloid Leukemia

Interventions

BIOLOGICAL: Daratumumab
PROCEDURE: Donor Lymphocyte Infusion
OTHER: Laboratory Biomarker Analysis

Sponsor

Sumithira Vasu